We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.21 | -12.962962963 | 1.62 | 1.68 | 1.39 | 381682 | 1.4477821 | CS |
4 | -0.65 | -31.5533980583 | 2.06 | 2.08 | 1.39 | 348424 | 1.69244782 | CS |
12 | -0.58 | -29.1457286432 | 1.99 | 2.355 | 1.39 | 413376 | 1.9222717 | CS |
26 | -0.63 | -30.8823529412 | 2.04 | 3.62 | 1.36 | 653598 | 2.12412636 | CS |
52 | -1.47 | -51.0416666667 | 2.88 | 3.62 | 1.3 | 452907 | 2.19464776 | CS |
156 | -26.89 | -95.0176678445 | 28.3 | 46.4 | 1.3 | 645832 | 18.26879507 | CS |
260 | -33.99 | -96.0169491525 | 35.4 | 53.762 | 1.3 | 608908 | 22.22985688 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions